AbstractThe emergence of treatment resistant sub-clones is a key feature of relapse in multiple myeloma. Therapeutic attempts to extend remission and prevent relapse include maximizing response and the use of maintenance therapy. We used whole exome sequencing to study the genetics of paired samples taken at presentation and at relapse from 56 newly diagnosed patients, following induction therapy, randomized to receive either lenalidomide maintenance or observation as part of the Myeloma XI trial. Patients included were considered high risk, relapsing within 30 months of maintenance randomization. Patients achieving a complete response had predominantly branching evolutionary patterns leading to relapse, characterized by a greater mutational burden, an altered mutational profile, bi-allelic inactivation of tumor suppressor genes, and acquired structural aberrations. Conversely, in patients achieving a partial response, the evolutionary features were predominantly stable with a similar mutational and structural profile seen at both time points. There were no significant differences between patients relapsing after lenalidomide maintenance versus observation. This study shows that the depth of response is a key determinant of the evolutionary patterns seen at relapse. This trial is registered at clinicaltrials.gov identifier: 01554852.
Multiple myeloma (MM) results from the malignant transformation of a normal plasma cell and has a mutational load which lies in an intermediate position between genetically simple malignancies, such as chronic myelogenous leukemia, and the more complex solid cancers.21 As such, MM provides an excellent model system through which to understand the mutational and evolutionary processes underlying disease relapse. MM is a genetically diverse condition, which is manifested by variations in clinical outcome even in uniformly treated populations.43
The treatment of newly diagnosed (ND) MM has improved over the last decade following the introduction of immunomodulatory drugs and proteasome inhibition, which, together with autologous stem cell transplantation, have increased the median overall survival from three to eight years.75 However, patients frequently relapse, and to improve outcomes further, strategies have been designed to eliminate the residual clonal cells that mediate relapse.108 In this context, an important strategy has been the use of maintenance therapy with lenalidomide.1311 This agent is well tolerated and has a bifunctional mode of action directly killing the tumor cells and enhancing the immune response to the malignant plasma cells that is mediated by directing Aiolos and Ikaros to the proteasome for degradation.1714
Understanding the features of residual cells that lead to relapse is an important challenge; however, this is technically difficult, especially in patients who have achieved stringent complete responses. One way of understanding the characteristics of cells in remission is to study the characteristics of cells at relapse. Previous studies of the genetic features of paired presentation and relapse samples have shown that, after intensive chemotherapy, bi-allelic loss of tumor suppressor genes, in particular TP53, and the deregulation of MYC by structural chromosomal changes are important features.18 In addition to mutational change, sub-clonal structure also varies at relapse and three main patterns have been described; branching, linear and shifting patterns of clonal dominance2318 (Table 1). Such analyses have not, however, studied uniformly treated patients for whom the depth of response or treatment information is available. To address the impact of maintenance and response depth on mutational patterns and clonal structure at relapse, we performed whole exome sequencing (WES) on paired presentation and relapse samples from 56 NDMM patients, 30 of whom had received lenalidomide maintenance and 26 who had not. All were treated at first presentation with a triple induction regimen containing an immunomodulatory agent, cyclophosphamide, and dexamethasone, making this the largest analysis of genetic evolution in a uniformly treated series of MM patients to date.
Samples were selected from NDMM patients enrolled into the Myeloma XI trial (clinicaltrials.gov identifier: 01554852) for whom adequate DNA volumes were available.24 The study was undertaken after written informed consent from patients and ethical approval was obtained from the Oxfordshire Research Ethics Committee (MREC 17/09/09, ISRCTN49407852). A nested case control analysis was performed on 56 patients who received either lenalidomide maintenance (n=30) or were observed (n=26) and subsequently relapsed2625 (Online Supplementary Figure S1). All patients included had phenotypical high-risk disease, defined as relapse within 30 months of maintenance randomization, irrespective of classical genetic risk status and best response. The median time from trial entry to relapse was 19 months, notably shorter than the progression-free survival (PFS) reported in the Myeloma XI trial of 35.9 and 32.9 months for patients treated with lenalidomide and thalidomide induction, respectively.27 Response was determined using International Myeloma Working Group (IMWG) criteria and a near complete response (nCR), defined as no detectable paraprotein, a normal light chain ratio, but where immunofixation and or bone marrow sampling was not performed or if immunofixation was positive. Prior to relapse, 21% (12 of 56) achieved a CR, 21% (12 of 56) a nCR, 42% (23 of 56) a very good partial response (VGPR), and 16% (9 of 56) a partial response (PR). To determine the impact of response on the genetic landscape at relapse we grouped patients according to the best response achieved prior to relapse, complete responders (CR/nCR) and non-complete responders (VGPR/PR). Clinical characteristics were well matched between the maintenance groups (Table 2). Patients’ characteristics according to induction regimen were also well matched (Online Supplementary Table S1).
DNA was isolated from plasma cells following selection using CD138 MACSorting (Miltenyi Biotech, Bisley, UK) from bone marrow aspirate samples. Control DNA was obtained from peripheral blood samples. Libraries for WES were prepared using the SureSelectQXT sample prep kit and the SureSelect Clinical Research Exome kit (Agilent), with additional baits covering the immunoglobulin and MYC loci, as previously described.28 Paired-end sequencing was performed to a median sequencing depth of 122× for tumor samples and 58× for controls using a HiSeq2500 (Illumina). Single nucleotide variants, including those of tumor suppressor genes and oncogenes, were determined using Strelka (v.1.0.14) and MuTect.3029 The distribution of mutant alleles determined by the variant allele frequency (VAF) was mapped using the R package SciClone.31 Cancer clonal fractions (CCF) were calculated for all mutations and plotted using Kernal density estimation to infer clonal structure at presentation and relapse.32
Copy number was assessed using both multiplexed ligation-dependant probe amplification (MLPA) (SALSA MLPA P425-B1 multiple myeloma probemix, MRC Holland, Amsterdam, the Netherlands) and the bioinformatics assessment tool Sequenza (v.2.1.2).3433 Paired MLPA and Sequenza data was available for 90 of 112 (80%) tumor samples, with a consensus between MLPA and Sequenza being seen in 85 of 90 samples (94%). For the five patients for whom a mismatch was observed, Sequenza was used to call the copy number profile. Translocations were determined using MANTA (v.0.29.3).35 For 46% (51 of 112) of patient samples, translocations involving the immunoglobulin heavy chain (IGH) were also assessed using multiplexed qRT-PCR.36 A consensus between MANTA and qRT-PCR was observed in 84% (43 of 51). In the eight patients for whom a mismatch was seen, the integrative genomics viewer (IGV) was used to confirm or exclude the translocation. All suspected bi-allelic copy number abnormality (CNA) events were confirmed by manual interrogation of BAM files using IGV. Bi-allelic inactivation was also called in patients with evidence of a non-synonymous mutation with mono-allelic loss or a single mutation with a VAF of ≥80%. A summary of the methods, bioinformatics tools and filters used to complete this analysis is available in Online Supplementary Figure S2.
Statistical analysis was performed using GraphPad Prism v.7.01 and R v.3.2.1. P=0.05 (two-sided) was considered statistically significant. Wilcoxon matched-pairs signed rank tests were conducted to determine significance between paired data sets, including the mutational load at presentation/relapse and PFS according to maintenance allocation, depth of response, and induction treatment. Fisher exact test was used to determine differences between two nominal variables, including the change in mutational profile from presentation to relapse and the evolutionary mechanism leading to relapse.
Relapse is characterized by a change in mutational spectrum
At presentation, genes mutated in >10% of patients were NRAS (23%, n=13), KRAS (23%, n=13), and DIS3 (13%, n=7) ((Figure 1A and B)). At relapse, TP53 was also seen in >10% of patients (11%, n=6). We examined genes that have previously been shown to be recurrently mutated in myeloma, including tumor suppressor genes, epigenetic modifiers, and genes within the RAS, NFκB and apoptosis pathways, the results of which are summarized (Figure C).44372818 Non-synonymous mutations were seen in one or more of these genes in 79% (44 of 56) of patients at presentation and 80% (45 of 56) at relapse. Importantly, gain and/or loss of one or more of these lesions at relapse was seen in 37% of patients (21 of 56), with 21% (12 of 56) of patients gaining a new lesion, 11% (6 of 56) losing a lesion, and 5% (3 of 56) both gaining and losing lesions. The most common new mutations at relapse were KRAS and PRDM1, both seen in 5% of patients (3 of 56), and NRAS and TP53, each seen in 4% (2 of 56). However, mutations in KRAS and NRAS were just as likely to be lost at relapse, with 5% (3 of 56) of patients losing KRAS mutations and 4% (2 of 56) losing NRAS (Figure 1B). The most commonly mutated pathway was the RAS-MAPK pathway, with mutations of one or more of NRAS, KRAS, BRAF, NF1, and EGFR being seen in 57% (33 of 56) of patients at some point during the disease course. Loss of one or more of these mutations was noted in 9% (5 of 56) of patients at relapse while new mutations were seen in 13% (7 of 56). The majority of these new mutations were clonal (CCF>80%) and all had a CCF >20% (range, 0.29-1) (Online Supplementary Figure S3). The results of these mutational studies are consistent with there being important changes in subclonal structure at relapse, rather than the simple accumulation of new mutations. The profile of mutations at presentation and relapse in patients who received lenalidomide or thalidomide induction was well matched (Online Supplementary Table S2).
Acquired structural change is a frequent feature of relapse
We interrogated regions of recurrent CNA that are known to be associated with prognosis: 1p32.3 (FAF1/CDKN2C), 1p12 (FAM46C), 13 (RB1), 14q (TRAF3), and 17p (TP53). Copy number loss of ≥1 of these regions was seen in 63% (35 of 56) of patients at presentation and 59% (33 of 56) at relapse (Online Supplementary Figure S4). There was an evident change in the profile at relapse, with regions of loss seen at presentation returning to a diploid status in 9% (5 of 56) of patients while new losses were seen in 13% (7 of 56). Once again, these features are consistent with an alteration in subclonal structure and a change in the nature of the dominant clone observed at relapse.
Gain(1q) was the most common new event at relapse, occurring in 13% (7 of 56) patients. Secondary translocations to chromosome 8q, the site of MYC, also occurred more frequently at relapse, increasing from 21% (12 of 56) to 27% (15 of 56) (Online Supplementary Table S3).45 Consistent with translocations to MYC being late events, five patients had evidence of two separate MYC translocations at relapse. All patients with gain(1q) or tMYC at presentation had evidence of the lesion at relapse, illustrating the driver status.
Bi-allelic inactivation of tumor suppressor genes located at sites of recurrent CNA are likely to be relevant mediators of relapse. We show that bi-allelic inactivation events of RB1, TRAF3, and TP53 are important with 18% (10 of 56) of patients having evidence of bi-allelic inactivation of ≥1 gene at relapse, in comparison to 14% (8 of 56) at presentation. One patient harboring both a TP53 mutation and del(17p) at presentation lost evidence of the del(17p) at relapse, but maintained bi-allelic inactivation via expansion of a different subclone characterized by a TP53 mutation which had a higher CCF at relapse (0.55 vs. 0.83).
Relapse following a complete response is characterized by a greater mutational load and a change in genetic profile
Patients achieving a CR had a significantly higher non-synonymous mutational load at relapse, with a median of 59 mutations compared to 40 at presentation (P<0.001). Non-CR patients had a similar mutational load at relapse, with a median of 39 mutations at both time points (P=0.63). Similar patterns were also seen in patients receiving or not receiving lenalidomide maintenance (Online Supplementary Table S4).
By comparing the profile of known recurrently mutated genes, we show that 67% (16 of 24) of CR cases had a change in mutational profile at relapse compared to only 25% (8 of 32) of non-CR cases (P=0.003) (Figure 2A); these findings were a feature of both the observation and lenalidomide maintenance series (Figure 2B and C). Consistent with the mutation profile changes described, gain and loss of the structural lesions del(1p), del(13), del(14), del(17p), gain (1q), and tMYC at relapse was more common in the CR series, with 42% (10 of 24) of patients having a change in the profile of these aberrations compared to 28% (9 of 32) of non-CR patients (Online Supplementary Figure 5S). The changes in mutational load could not be linked to a change in the number of clones predicted by SciClone clustering, where a median number of seven clones was seen at relapse in both the CR and non-CR series (Figure 3). The same findings were noted for all 56 patients and when analyzed according to maintenance strategy. No patient had evidence of the loss or gain of >2 mutational clusters at relapse, further suggesting that a change in the number of clones is not a major cause for change in the mutational load (Online Supplementary Table S5).
Lenalidomide maintenance has no impact on the mutational profile at relapse
There was no specific mutational, copy number or structural feature which characterized patients who received lenalidomide maintenance compared to observation patients. Of patients who received lenalidomide maintenance, 83% (25 of 30) had a mutation in one or more of the recurrently mutated myeloma genes at some point during the disease course compared to 85% (22 of 26) of observation patients. Gain and/or loss of one or more mutation at relapse, including those in genes implicated in the mechanism of action of an immunomodulatory agent, were seen in 43% (13 of 30) of patients receiving lenalidomide maintenance and 35% (9 of 26) of the observation patients (Figure 1B).
We did not identify a mutational signal consistent with the selection of clones carrying mutations associated with acquired resistance to lenalidomide. Five patients had mutations in DDB1 (n=2), SLC16A1 (n=2), and CRBN (n=1), but these were not confined to the cases of lenalidomide maintenance, nor were they seen exclusively at relapse (Figure 1B). Mutations in other genes linked to the mechanism of action of lenalidomide, including regulator of cullins 1, cullin-4A, Ikaros, Aiolos, and Basigin, were not found at presentation or relapse in any patient.484614 Mutations in MYC and IRF4, transcription factors known to be down-regulated in response to immunomodulation, were seen in 2% (n=1) and 4% (n=2) of patients, respectively. However, consistent with an acquired mutation having a possible role in drug resistance, we identified one patient who had been exposed to eight months of lenalidomide maintenance and achieved flow cytometric minimal residual disease (MRD) negativity (minimum 5×10 cells interrogated) and who then went on to develop a novel CRBN mutation (p.Cys326Gly) at relapse; this is consistent with the emergence of resistance due to mutation at the immunomodulatory molecule binding site. The mutation was also present in a dominant clone, with a CCF of 0.71, further suggesting its presence may have impacted on the fitness of the tumor in relation to pressure from the immunomodulatory treatment (Online Supplementary Figure S6).
Branching evolution is the predominant process leading to relapse, particularly in patients achieving a deep treatment response
We observed three main evolutionary patterns at relapse: branching, linear, and stable. Branching evolution was characterized by both gain and loss of mutational clusters and was the predominant pattern, seen in 66% (37 of 56) of all cases (Figure 4A). Linear evolution characterized only by the gain of mutations at relapse was seen in 20% (11 of 56) of cases (Figure 4B). The remaining 14% (8 of 56) had either the same mutational profile at both time points, and were classified as stable progression (n=7), or displayed a loss of a mutational cluster at relapse, classified as stable progression with clone loss (n=1) (Figure 4C and D). There was no significant impact of induction or maintenance lenalidomide on the evolutionary pattern seen at relapse (Online Supplementary Figure S7).
We show that the depth of treatment response is the most important determinant of the evolutionary pattern seen at relapse. Although branching evolution was dominant in both the CR and non-CR series, stable progression was only seen in the non-CR series, (25%, 8 of 32, vs. 0%, 0 of 25; P=0.008) (Figure 5A). Breaking down the non-CR series further showed that stable progression was predominantly associated with a PR (56%, 5 of 9 of PR; 13%, 3 of 23 of VGPR patients). No CR or nCR patients (0 of 24) had evidence of stable progression, with all patients showing branching or linear evolution (P=0.002) (Figure 5B). Consistent with a deep response being synonymous with a change in clonal architecture, 86% (6 of 7) of patients who achieved an MRD-negative state relapsed via a branching mechanism and 14% (1 of 7) via linear evolution. The type of evolution leading to relapse had no impact on the time to relapse or overall survival (Online Supplementary Table S6).
This study shows that an increase in mutational load, altered mutational profile, accumulation of deleterious structural lesions [particularly tMYC and gain(1q)], and a change in copy number profile are key molecular features of relapse. The depth of response to treatment has a significant impact on both the genetic landscape and the evolutionary patterns seen at relapse, with an increased mutational load being predominantly associated with the achievement of a CR. We also note that relapse from CR is associated with an altered mutational profile, with 63% (15 of 24) of the CR patients having evidence of loss or gain of known recurrently mutated genes in comparison to only 25% (8 of 32) of non-CR patients (P=0.006). This pattern was also seen for CNA and structural variants, with del(17p), tMYC, gain(1q), and loss of tumor suppressor gene regions, including CDKN2C, FAF1, FAM46C, RB1, and TRAF3, being seen more frequently in the patients relapsing after CR.
It has been shown that the progression through the multistep transformation of MM is associated with an increased mutational load. This is well illustrated by studies that have compared monoclonal gammopathy of undetermined significance, MM, and plasma cell leukemia. Our results are consistent with this observation, and we clearly show that an increased mutational load is an important factor in early disease progression following a good response to treatment.5049 Similar findings are observed in other cancer types where a greater mutational load is associated with a more aggressive disease status, for example, lung cancer in smokers compared to nonsmokers, and in malignant melanoma.5251
A variety of subclonal patterns, including branching, linear, and stable patterns, are seen at relapse (Figure 4A-D). The pattern of clonal change is most consistent with the hypothesis that branching evolutionary pathways are the predominant mechanism underlying relapse, especially if spatial variation is taken into account. Treatment can be seen as causing an evolutionary bottleneck, particularly in patients who achieve a deep treatment response, providing a selective pressure for the emergence of pre-existent resistant clones. Importantly, these branching patterns and increased genetic damage in the clonal cells are hallmarks of effective treatment and achievement of deep responses. In contrast, the stable patterns seen in non-CR patients are most consistent with microenvironmental change, possibly as a consequence of the presence of treatment resistant dominant clones at disease onset. This stable pattern is reminiscent of the results seen in the progression of smoldering MM to MM, where the emergence of new mutations is infrequent, yet there is a profound change in clinical behavior.
Mechanistically, relapse in the setting of effective therapy that results in the achievement of a CR is occurring either due to the emergence of low-level sub-clones that are undetectable at presentation, but which are selected for by treatment, or as a result of the acquisition of new mutations, albeit less likely given the short duration of remission. It may also be that the differences seen are the result of sampling bias, as previously shown by our group, although this is less likely given that all biopsies were obtained from the pelvis.53 The pattern of results seen with eradication of dominant clones and emergence of low-level clones with different pattern of mutation, and its association with CR, supports the concept that treatment can result in subclonal eradication. These findings highlight the therapeutic importance of achieving a CR to eradicate dominant clones present at the initiation of therapy. Supporting this as a therapeutic aim, we have recently shown that high-risk patients achieving a molecular CR have very significantly improved 5-year survival rates.54
The results show that, even in MRD-negative CR, low-level resistant subclones remain, and therapeutic strategies need to be designed to address them. We believe this work supports the current best practice strategy of using different treatment regimens at successive relapses and shows why this approach is successful. We show that early relapse is either due to innate treatment resistance, requiring no change in the clonal structure, or due to a change of clonal architecture in response to effective therapy. Both mechanisms are consistent with a disease state at relapse that is resistant to the initial therapies used. This knowledge supports the use of combination regimens at relapse, incorporating agents with differing mechanisms of action to those used at presentation. This will be analyzed in a planned comparator series of patients who achieve long-term remission in the trial. Our work here does, however, provide new insights into the mechanisms of early relapsing disease, revealing a different mechanism in those who achieve a deep therapeutic response and those who do not.
Interestingly, a recent study looking at non-small cell lung cancer has shown that mutational load may direct treatment choices, whereby the use of immunotherapy was associated with a longer and durable remission in patients with a greater mutational load at presentation.55 Therefore, as our understanding of myeloma biology increases, information such as mutational load may guide specific treatment modalities in the future. The use of lenalidomide maintenance is one of the first clinical strategies to address the residual cells that remain following initial treatment. Using this approach, we did not see a signal of any adverse impact on the clonal cells as a result of this therapy. In particular, we did not see a signal for selection of mutations that could confer resistance to lenalidomide either at presentation or at relapse. Previous studies have suggested that such mutations may exist and could be relatively frequent in cell lines and heavily pre-treated patients, but in this study of newly diagnosed patients they were rare.56 However, we do describe a patient who received eight months of maintenance treatment, achieving an MRD-negative CR who did relapse with a new CRBN mutation. It is likely that the mutation occurred by chance, but that, in true Darwinian fashion, in the presence of lenalidomide, it conferred a survival advantage to the malignant cells harboring it. Recent analyses indicating that prolonged exposure to lenalidomide is not linked to an increased incidence of second primary hematologic malignancies when used in combinations excluding oral melphalan may be supported by a lack of evidence of mutagenesis leading to treatment resistance in this work, although it is acknowledged that larger analyses using patients with prolonged remissions are required.5724 It is important to note that the patients studied here relapsed early and that they were selected because of this characteristic, as it had previously been suggested that exposure to lenalidomide could enhance progression of such cases post maintenance. However, we did not find any evidence to support such a hypothesis.
It does remain important to evaluate the impact of maintenance on low-risk cases who are long-term survivors, a question not addressed in this study. In addition, we acknowledge that clonal structure may be further assessed using single cell analysis. However, for the moment, the challenges of obtaining individual malignant plasma cells from large series of patients at multiple disease time points has proved to be a significant barrier. In this series of patients, however, we do see evidence of parallel evolution, as previously described using single cell technology, further validating the clonal changes described here.23 An example is seen in a patient with bi-allelic inactivation of TP53 at presentation characterized by del(17p) and TP53 mutation, but only the presence of a TP53 mutation at relapse. In this case the clone with del(17p) was no longer detectable at relapse, suggesting it was treatment sensitive and/or out-completed by a more aggressive treatment insensitive clone harboring a TP53 mutation that had expanded following treatment, confirmed by a higher CCF at relapse (0.55 vs. 0.83).
In this group of high-risk early-relapsing patients, we show that relapse is a result of the dynamic interplay of evolutionary processes based on the capacity of clonal cells to adapt to their bone marrow microenvironment as a result of new mutations, copy number change, and the selective pressure of the treatment used. Specifically, the depth of response is a critical feature that impacts the evolutionary patterns seen at relapse, rather than the use of lenalidomide maintenance.
We are thankful to all the patients who have taken part in the Myeloma XI trial, from which samples used in this analysis were obtained. We thank the Data Monitoring and Ethics Committee (DMEC) and Trial Steering Group Committee (TSG) for their support and guidance throughout the trial.
- Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/104/7/1440
- FundingMyeloma XI was funded by Cancer Research UK and received unrestricted educational grants from Celgene, Takeda and Merck.
- Received August 31, 2018.
- Accepted January 30, 2019.
- Kandoth C, McLellan MD, Vandin F. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471):333-339. PubMedhttps://doi.org/10.1038/nature12634Google Scholar
- Lawrence MS, Stojanov P, Polak P. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PubMedhttps://doi.org/10.1038/nature12213Google Scholar
- Lonial S, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia. 2014; 28(2):258-268. PubMedhttps://doi.org/10.1038/leu.2013.220Google Scholar
- Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017; 17(9):543-556. Google Scholar
- Kumar SK, Dispenzieri A, Lacy MQ. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014; 28(5):1122-1128. PubMedhttps://doi.org/10.1038/leu.2013.313Google Scholar
- Kumar SK, Rajkumar SV, Dispenzieri A. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111(5):2516-2520. PubMedhttps://doi.org/10.1182/blood-2007-10-116129Google Scholar
- Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist. 2011; 16(11):1600-1603. PubMedhttps://doi.org/10.1634/theoncologist.2011-0229Google Scholar
- Rawstron AC, Gregory WM, de Tute RM. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015; 125(12):1932-1935. PubMedhttps://doi.org/10.1182/blood-2014-07-590166Google Scholar
- Oliva S, Gambella M, Gilestro M. Minimal residual disease after transplanta tion or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oncotarget. 2017; 8(4):5924-5935. Google Scholar
- Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015; 125(20):3059-3068. PubMedhttps://doi.org/10.1182/blood-2014-11-568907Google Scholar
- Attal M, Lauwers-Cances V, Marit G. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366(19):1782-1791. PubMedhttps://doi.org/10.1056/NEJMoa1114138Google Scholar
- Palumbo A, Hajek R, Delforge M. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012; 366(19):1759-1769. PubMedhttps://doi.org/10.1056/NEJMoa1112704Google Scholar
- McCarthy PL, Owzar K, Hofmeister CC. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366(19):1770-1781. PubMedhttps://doi.org/10.1056/NEJMoa1114083Google Scholar
- Bjorklund CC, Lu L, Kang J. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 2015; 5:e354. PubMedhttps://doi.org/10.1038/bcj.2015.66Google Scholar
- Fischer ES, Bohm K, Lydeard JR. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014; 512(7512):49-53. PubMedhttps://doi.org/10.1038/nature13527Google Scholar
- Lopez-Girona A, Mendy D, Ito T. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012; 26(11):2326-2335. PubMedhttps://doi.org/10.1038/leu.2012.119Google Scholar
- Quach H, Ritchie D, Stewart AK. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010; 24(1):22-32. PubMedhttps://doi.org/10.1038/leu.2009.236Google Scholar
- Weinhold N, Ashby C, Rasche L. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016; 128(13):1735-1744. PubMedhttps://doi.org/10.1182/blood-2016-06-723007Google Scholar
- Keats JJ, Chesi M, Egan JB. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012; 120(5):1067-1076. PubMedhttps://doi.org/10.1182/blood-2012-01-405985Google Scholar
- Magrangeas F, Avet-Loiseau H, Gouraud W. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia. 2013; 27(2):473-481. PubMedhttps://doi.org/10.1038/leu.2012.226Google Scholar
- Bolli N, Avet-Loiseau H, Wedge DC. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014; 5:2997. PubMedhttps://doi.org/10.1038/ncomms3997Google Scholar
- Kortum KM, Langer C, Monge J. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P). Ann Hematol. 2015; 94(7):1205-1211. PubMedhttps://doi.org/10.1007/s00277-015-2344-9Google Scholar
- Melchor L, Brioli A, Wardell CP. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia. 2014; 28(8):1705-1715. PubMedhttps://doi.org/10.1038/leu.2014.13Google Scholar
- Jones JR, Cairns DA, Gregory WM. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016; 6(12):e506. Google Scholar
- Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-346. PubMedhttps://doi.org/10.1016/S1470-2045(16)30206-6Google Scholar
- Durie BG, Harousseau JL, Miguel JS. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20(9):1467-1473. PubMedhttps://doi.org/10.1038/sj.leu.2404284Google Scholar
- Jackson Graham H, Davies Faith, Pawlyn Charlotte. Lenalidomide induction and maintenance therapy for transplant eligible myeloma patients: Results of the Myeloma XI study. J Clin Oncol. 2017; 35(15_suppl):8009-8009. Google Scholar
- Walker BA, Wardell CP, Murison A. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015; 6:6997. PubMedhttps://doi.org/10.1038/ncomms7997Google Scholar
- Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics (Oxford, England). 2012; 28(14):1811-1817. PubMedhttps://doi.org/10.1093/bioinformatics/bts271Google Scholar
- Cibulskis K, Lawrence MS, Carter SL. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-219. PubMedhttps://doi.org/10.1038/nbt.2514Google Scholar
- Miller CA, White BS, Dees ND. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol. 2014; 10(8):e1003665. PubMedhttps://doi.org/10.1371/journal.pcbi.1003665Google Scholar
- Stephens PJ, Tarpey PS, Davies H. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-404. PubMedhttps://doi.org/10.1038/nature11017Google Scholar
- Boyle EM, Proszek PZ, Kaiser MF. A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma. Genes Chromosomes Cancer. 2015; 54(2):91-98. Google Scholar
- Favero F, Joshi T, Marquard AM. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann Oncol. 2015; 26(1):64-70. PubMedhttps://doi.org/10.1093/annonc/mdu479Google Scholar
- Rausch T, Zichner T, Schlattl A, Stutz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics (Oxford, England). 2012; 28(18):i333-i339. PubMedhttps://doi.org/10.1093/bioinformatics/bts378Google Scholar
- Kaiser MF, Walker BA, Hockley SL. A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR. Leukemia. 2013; 27(8):1754-1757. PubMedhttps://doi.org/10.1038/leu.2013.12Google Scholar
- Walker BA, Boyle EM, Wardell CP. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015; 33(33):3911-3920. PubMedhttps://doi.org/10.1200/JCO.2014.59.1503Google Scholar
- Lohr JG, Stojanov P, Carter SL. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014; 25(1):91-101. PubMedhttps://doi.org/10.1016/j.ccr.2013.12.015Google Scholar
- Chapman MA, Lawrence MS, Keats JJ. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471(7339):467-472. PubMedhttps://doi.org/10.1038/nature09837Google Scholar
- Pawlyn C, Kaiser MF, Heuck C. The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. Clin Cancer Res. 2016; 22(23):5783-5794. PubMedhttps://doi.org/10.1158/1078-0432.CCR-15-1790Google Scholar
- Heuck C, Johann D, Walker BA. Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling. Blood. 2014; 124(21):3418. Google Scholar
- Boone DN, Qi Y, Li Z, Hann SR. Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism. Proc Natl Acad Sci U S A. 2011; 108(2):632-637. PubMedhttps://doi.org/10.1073/pnas.1008848108Google Scholar
- Joslin JM, Fernald AA, Tennant TR. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood. 2007; 110(2):719-726. PubMedhttps://doi.org/10.1182/blood-2007-01-068809Google Scholar
- Gabrea A, Martelli ML, Qi Y. Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. Genes Chromosomes Cancer. 2008; 47(7):573-590. PubMedhttps://doi.org/10.1002/gcc.20563Google Scholar
- Walker BA, Wardell CP, Brioli A. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J. 2014; 4:e191. PubMedhttps://doi.org/10.1038/bcj.2014.13Google Scholar
- Eichner R, Heider M, Fernandez-Saiz V. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med. 2016; 22(7):735-743. PubMedhttps://doi.org/10.1038/nm.4128Google Scholar
- Giagounidis A, Mufti GJ, Fenaux P, Germing U, List A, MacBeth KJ. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Ann Hematol. 2014; 93(1):1-11. PubMedhttps://doi.org/10.1007/s00277-013-1863-5Google Scholar
- Ito T, Ando H, Suzuki T. Identification of a primary target of thalidomide teratogenicity. Science. 2010; 327(5971):1345-1350. PubMedhttps://doi.org/10.1126/science.1177319Google Scholar
- Walker BA, Wardell CP, Melchor L. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014; 28(2):384-390. PubMedhttps://doi.org/10.1038/leu.2013.199Google Scholar
- Mikulasova A, Wardell CP, Murison A. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica. 2017; 102(9):1617-1625. PubMedhttps://doi.org/10.3324/haematol.2017.163766Google Scholar
- Rizvi NA, Hellmann MD, Snyder A. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-128. PubMedhttps://doi.org/10.1126/science.aaa1348Google Scholar
- Govindan R, Ding L, Griffith M. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012; 150(6):1121-1134. PubMedhttps://doi.org/10.1016/j.cell.2012.08.024Google Scholar
- Rasche L, Chavan SS, Stephens OW. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017; 8(1):268. https://doi.org/10.1038/s41467-017-00296-yGoogle Scholar
- Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014; 124(20):3043-3051. PubMedhttps://doi.org/10.1182/blood-2014-07-552059Google Scholar
- Lyu GY, Yeh YH, Yeh YC, Wang YC. Mutation load estimation model as a predictor of the response to cancer immunotherapy. NPJ Genom Med. 2018; 3:12. Google Scholar
- Kortum KM, Mai EK, Hanafiah NH. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016; 128(9):1226-1233. PubMedhttps://doi.org/10.1182/blood-2016-02-698092Google Scholar
- Palumbo A, Bringhen S, Kumar SK. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014; 15(3):333-342. PubMedhttps://doi.org/10.1016/S1470-2045(13)70609-0Google Scholar